睿知中国医院研究地图
候选清单

正在招募乳腺癌I/II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor

ClinicalTrials.gov 上登记的一项乳腺癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心复旦大学附属肿瘤医院Fudan University Shanghai Cancer Center上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07612891,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Patients with histologically or cytologically confirmed unresectable locally advanced or metastatic solid tumors, who have disease progression following standard-of-care therapy, are intolerant to standard treatment, or have no available standard treatment options (e.g., HR+/HER2- breast cancer, Cyclin E1-overexpressing solid tumors and other solid tumors).

    入选标准第 3 条

    Agree to provide available archived FFPE tumor tissue specimens or voluntarily accept pre-treatment tumor biopsy (Phase Ⅱ).

    入选标准第 4 条

  3. Have received any anti-tumor therapy or participated in other therapeutic clinical trial within 28 days prior to the first dose of study drug.

    排除标准第 3 条

    Has undergone major surgery within 28 days prior to the first dose of study drug.

    排除标准第 4 条

    Diagnosed with immunodeficiency or received any form of immunosuppressive therapy within 7 days prior to the first dose.

    排除标准第 6 条

    Have received prior CDK2 inhibitors.

    排除标准第 16 条

  4. ECOG performance status 0-1.

    入选标准第 7 条

  5. Have RECIST 1.1-defined measurable lesions.

    入选标准第 5 条

  6. Confirmed infection with HIV, HBV or HCV.

    排除标准第 14 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07612891,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Written informed consent obtained.
  2. Adult patients aged ≥ 18 years.
  3. Patients with histologically or cytologically confirmed unresectable locally advanced or metastatic solid tumors, who have disease progression following standard-of-care therapy, are intolerant to standard treatment, or have no available standard treatment options (e.g., HR+/HER2- breast cancer, Cyclin E1-overexpressing solid tumors and other solid tumors).
  4. Agree to provide available archived FFPE tumor tissue specimens or voluntarily accept pre-treatment tumor biopsy (Phase Ⅱ).
  5. Have RECIST 1.1-defined measurable lesions.
  6. Has a life expectancy of > 3 months.
  7. ECOG performance status 0-1.
  8. Adequate marrow, liver and kidney function.
  9. Meet the study's specified contraceptive requirements.

排除标准:Exclusion Criteria:

  1. Have a second primary malignancy.
  2. Patients with primary CNS tumors or CNS metastases with prior local treatment failure.
  3. Have received any anti-tumor therapy or participated in other therapeutic clinical trial within 28 days prior to the first dose of study drug.
  4. Has undergone major surgery within 28 days prior to the first dose of study drug.
  5. Prior anti-tumor therapy-related toxicities have not recovered to protocol-specified grades.
  6. Diagnosed with immunodeficiency or received any form of immunosuppressive therapy within 7 days prior to the first dose.
  7. Patients with other severe and persistent underlying medical conditions as assessed by the Investigator.
  8. Have protocol-defined clinically significant cardiovascular diseases.
  9. Prolonged QTcF interval.
  10. Have any medical conditions likely to impair digestion and absorption of the investigational product.
  11. Patients with poorly managed blood glucose levels and blood pressure.
  12. Clinically significant abnormal serum potassium or sodium as judged by the investigator.
  13. Have experienced a severe concurrent infection 14 days prior to the first dose of study drug.
  14. Confirmed infection with HIV, HBV or HCV.
  15. Are currently receiving any other investigation agent.
  16. Have received prior CDK2 inhibitors.
  17. Patients with known hypersensitivity to the study drug or any of its components.
  18. History of allogenic tissue or solid organ transplant.
  19. Are unwilling or unable to comply with procedures required in this protocol.
  20. Has other severe systemic diseases or for other reasons deemed ineligible for participation in this clinical trial by the investigator.

引自 ClinicalTrials.gov, NCT07612891, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07612891,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07612891